Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's
Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous
Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of
Therapy
Head/Neck
Phase III
Adults
Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics
ASP-1929, Cetuximab, Docetaxel (Taxotere), Methotrexate, Paclitaxel
Mannion, Kyle
International
Vanderbilt University
10-27-2020
Treatment
VICCHN1927
NCT03769506

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Have a histologically confirmed locoregional persistent, recurrent or second primary squamous cell carcinoma of the head and neck, not amenable to curative treatment

Have failed or progressed on or after at least 2 lines of therapy for squamous cell carcinoma of the head and neck, one of which must be prior systemic platinum-based chemotherapy

Have completed prior curative radiation therapy for treatment of their head and neck region

Have locoregional head and neck tumor site(s) that are all accessible to illumination

Have target tumors that are clearly measurable by contract enhanced CT scan

Have a life expectancy of > 6 months, based on Investigator judgment

Male participants must agree to use contraception during the treatment period and for at least 6 months after the last ASP-1929 infusion

Female patients of childbearing potential must not be pregnant or breastfeeding and agrees to follow the contraceptive guidance during the treatment period and for at least 6 months after the last dose of trial intervention and must refrain from breastfeeding for at least 2 months after the last ASP-1929 infusion

Have an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1



Exclusion Criteria:

Have a history of significant (> Grade 3) cetuximab infusion reactions

Have been treated with prior systematic chemotherapy or targeted small molecule therapy or radiation therapy within 2 weeks of trial Day 1 or not recovered from adverse events due to a previously administered agent

Have been treated with an anticancer monoclonal antibody therapy within 4 of trial Day 1 or have not recovered from adverse events due to previously administered agent

Have been treated with an investigational agent or intervention within 4 weeks of trial Day 1 or have not recovered from adverse events, due to previously administered agent or intervention

Have a present history of distant metastatic disease (M1)

Have an active undergoing treatment or have a diagnosis of an active cancer other than nonmelanoma skin cancer or HNSCC

Have a tumor in enhanced CT or MRI scan invading a major blood vessel, unless the vessel has been embolized, stented or surgically ligated to prevent potential bleeding from a blood vessel

Have impaired hepatic function

Have impaired renal function

Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with trial requirements

Have been previously treated or randomized to any trial using ASP-1929 or RM-1929 PIT as the study treatment

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: